- Philip Morris International Inc (NYSE:PM) has agreed to acquire Fertin Pharma, a Denmark-based developer and manufacturer of pharmaceutical and well-being products.
- The enterprise value of the deal is about $820 million.
- The transaction value represents a multiple of around 15 times Fertin Pharma’s 2020 EBITDA.
- Upon the completion of the acquisition, Fertin Pharma will become a wholly-owned subsidiary of Philip Morris.
- The transaction is expected to close in the fourth quarter of 2021.
- “The acquisition of Fertin Pharma will be a significant step forward on our journey toward delivering a smoke-free future—enhancing our smoke-free portfolio, notably in modern oral, and accelerating our progress in beyond nicotine,” stated Jacek Olczak, Chief Executive Officer.
- Philip Morris’s cash and equivalents totaled $3.9 billion.
- Price action: PM shares are trading higher by 1.04% at $100.14 on the last check Thursday.
Raymond James Maintains Strong Buy on Polaris, Lowers Price Target to $148
Raymond James analyst Joseph Altobello maintains Polaris (NYSE:PII) with a Strong Buy and lowers the price target from $158 to $148.
